MedincellMEDCL 
-0.77%24h
Medincell (MEDCL) Stock Overview
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for organ transplant; mdc-WWM for contraception; mdc-STM for malaria; and mdc-IRM for neuroscience. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
MEDCL Stock Information
Medincell (MEDCL) Price Chart
Medincell Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $20.12 | N/A |
| Market Cap | $506.80M | N/A |
| Shares Outstanding | 25.19M | 1.30% |
| Employees | 138.00 | N/A |
| Shareholder Equity | -42.29M | 216.31% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -15.84 | N/A |
| P/S Ratio | 46.00 | N/A |
| P/B Ratio | -11.98 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | 0.8385 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $11.02M | N/A |
| Earnings | -$35.47M | N/A |
| EPS | -1.27 | N/A |
| Earnings Yield | -0.0631 | N/A |
| Operating Margin | -2.42 | N/A |
| Net income margin | -3.22 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $32.51M | N/A |
| Total Debt | $63.94M | N/A |
| Cash on Hand | $7.17M | N/A |
| Debt to Equity | -1.8765 | -60.73% |
| Cash to Debt | 0.1121 | -79.98% |
| Current Ratio | 0.3431 | -61.49% |
